发明名称 Use of sodium channel blocker in the manufacture of a medicament for preventing optic nerve degeneration associated with glaucoma
摘要 A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na+ via non-inactivating Na+ channels, and the lethal elevation of cell Ca2+ due to reversal of the Na+/Ca2+ exchanger. The method includes blocking, by administration of a selected composition, of associated, non-inactivating Na+ channels in retinal ganglion cells in order to limit Na+/Ca+ exchange in the retinal ganglion cells and prevent buildup of the Ca2+ level in the retinal ganglion cells to a lethal level. The results in a method of preventing retinal ganglion cell death, associated with glaucoma, by administering to the optic nerve of a mammal, a compound which blocks the non-inactivating sodium ion channels of the optic nerve. Alternately, said invention relates to a method of preventing optic retinal ganglion cell death in a human by administering to the retinal ganglion cells of said human a compound which blocks the non-inactivating sodium ion channel of the retinal ganglion cells.
申请公布号 AU6776298(A) 申请公布日期 1998.10.22
申请号 AU19980067762 申请日期 1998.03.26
申请人 ALLERGAN 发明人 JOSEPH S ADORANTE
分类号 A61K9/08;A61K9/00;A61K31/428;A61K31/496;A61K45/00;A61P27/06;A61P43/00 主分类号 A61K9/08
代理机构 代理人
主权项
地址